ライフサイエンスコーパス: renal cell cancer

1 kidney cancer (hereditary leiomyomatosis and renal cell cancer).

2 ients with metastatic malignant melanoma and renal cell cancer.

3 and lymphoid malignancies and in metastatic renal cell cancer.

4 romosome 10q deletion in primary bladder and renal cell cancer.

5 lected patients with metastatic melanoma and renal cell cancer.

6 on itself, may contribute to the etiology of renal cell cancer.

7 metastatic malignant melanoma or metastatic renal cell cancer.

8 Odds ratios were not elevated for renal cell cancer.

9 mas as well as hereditary leiomyomatosis and renal cell cancer.

10 th melanoma, non-small-cell lung cancer, and renal cell cancer.

11 ond-line therapy in patients with metastatic renal cell cancer.

12 st, lung, ovarian, pancreatic, prostate, and renal cell cancer.

13 ts and therefore may also reduce the risk of renal cell cancer.

14 lescence, is associated with reduced risk of renal cell cancer.

15 cence were associated with a reduced risk of renal cell cancer.

16 for human bladder, head and neck, lung, and renal cell cancer.

17 ition syndrome hereditary leiomyomatosis and renal cell cancer.

18 significant activity of PS-341 in metastatic renal cell cancer.

19 e inhibitor PS-341 in patients with stage IV renal cell cancer.

20 ydratase cause hereditary leiomyomatosis and renal cell cancer.

21 myoma syndrome (MCL) and MCL associated with renal cell cancer.

22 cated as risk factors for the development of renal-cell cancer.

23 ith non-small-cell lung cancer, melanoma, or renal-cell cancer.

24 nhibitors approved for treatment of advanced renal-cell cancer.

25 ng non-small-cell lung cancer, melanoma, and renal-cell cancer.

26 ssion of disease in patients with metastatic renal-cell cancer.

27 n 65 of 285 (23%) bladder and 15 of 60 (25%) renal cell cancers.

28 herin-6 expression in a series of 32 primary renal cell cancers.

29 mary head and neck, non-small cell lung, and renal cell cancers.

30 odels and in some patients with melanoma and renal cell cancers.

31 melanoma, 18 with colorectal cancer, 17 with renal-cell cancer, 17 with ovarian cancer, 14 with pancr

32 Of the 201 patients with renal cell cancer, 18 achieved CRs and 20 PRs, for an ov

33 9 of 52 patients with melanoma, 2 of 17 with renal-cell cancer, 5 of 49 with non-small-cell lung canc

34 Of the 15 DTCs, 6 were renal cell cancer; 5, lung cancer; 2, lymphoma; 1, neuro

35 of 94 patients), and 27% among patients with renal-cell cancer (9 of 33 patients).

36 est that the flavonoid quercetin may prevent renal cell cancer among male smokers.

37 y, further etiologic research is needed into renal cell cancer, an increasingly common form of cancer

38 isk of upper urinary tract cancer, including renal cell cancer and cancers of the renal pelvis or ure

39 udies in untreated patients with melanoma or renal cell cancer and in other rhIL-12-responsive malign

40 mutation in von Hippel-Lindau (VHL) develop renal cell cancers and hypervascular tumors of the brain

41 All renal cell cancers and most breast cancers, non-Hodgkin

42 FR) inhibitor under clinical development for renal-cell cancer and other solid tumors.

43 or former smokers had a greater risk of both renal-cell cancer and renal-pelvis cancer than men who w

44 nal stromal tumours, neuroendocrine cancers, renal-cell cancer and sarcoma is associated with longer

45 derlying malignancy (renal cell cancer v non-renal cell cancer) and TKI (sunitinib v sorafenib), but

46 substantially lower the overall incidence of renal cell cancer, and 2) intervention measures may have

47 oval for the treatment of advanced melanoma, renal cell cancer, and non-small cell lung cancer.

48 ghths had a 30 to 60 percent greater risk of renal-cell cancer, and men in the highest two eighths ha

49 oliferative diseases, colorectal cancer, and renal cell cancer being the most common.

50 re enrolled into Medicare and diagnosed with renal cell cancer between 1986 and 1999.

51 ed for treatment of patients with metastatic renal-cell cancer, but no validated biomarkers are avail

52 e primary tumors of patients with metastatic renal cell cancer by using cDNA microarrays.

53 de that survival in patients with metastatic renal cell cancer can be correlated with the expression

54 rate among blacks compared with whites with renal cell cancer can be explained largely by the increa

55 After 8.3 years of follow-up, 347 renal cell cancer cases (220 men, 127 women) were identi

56 thors present estimates of the proportion of renal cell cancer cases attributable (or population attr

57 Clear cell renal cell cancer (CC-RCC) is a highly chemoresistant tu

58 e and also occur in most sporadic clear cell renal cell cancers (CCRCC).

59 l common malignancies, for example colon and renal cell cancer, code for ubiquitin ligase components.

60 Clear-cell renal cell cancer (CRCC) is initiated typically by loss

61 Analysis included 335 renal cell cancer deaths (123 in women and 212 in men).

62 ts, 21 of 23 with melanoma and 34 of 38 with renal cell cancer developed at least PRs after the first

63 open radical nephrectomy for the majority of renal cell cancers due to equivalent oncologic control,

64 d a unique association of MN expression with renal cell cancers, especially those of the clear cell v

65 patient with melanoma, and one patient with renal cell cancer had complete regression of pulmonary m

66 for a relation between physical activity and renal cell cancer has been inconsistent.

67 The value of nephrectomy in metastatic renal-cell cancer has long been debated.

68 Black patients with renal cell cancer have shorter survival compared with th

69 Hereditary leiomyomatosis and renal cell cancer (HLRCC) is an autosomal dominant disor

70 Hereditary leiomyomatosis and renal cell cancer (HLRCC) is an inherited cancer syndrom

71 mata (MCL) and hereditary leiomyomatosis and renal cell cancer (HLRCC), and recently, FH mutations ha

72 a rare cancer, hereditary leiomyomatosis and renal cell cancer (HLRCC), characterised by benign smoot

73 CUL1), and the hereditary leiomyomatosis and renal cell cancer (HLRCC), implicated FH, a gene on chro

74 FH predispose individuals to leiomyomas and renal cell cancer (HLRCC), whereas mutations in SDH caus

75 drome known as hereditary leiomyomatosis and renal cell cancer (HLRCC).

76 esponsible for hereditary leiomyomatosis and renal-cell cancer (HLRCC).

77 ar relative survival rates for patients with renal cell cancer improved among whites but not among bl

78 rs examined physical activity in relation to renal cell cancer in a large, prospective US cohort stud

79 ostatin at 10 mg/kg suppressed the growth of renal cell cancer in a nude mouse model.

80 ypertensive medications to the risk of fatal renal cell cancer in a prospective cohort study of 998,9

81 predispose to hereditary leiomyomatosis and renal cell cancer in affected individuals.

82 oking, and hypertension are risk factors for renal cell cancer in both sexes.

83 uting to the rapidly increasing incidence of renal cell cancer in the United States, particularly amo

84 pment of cutaneous and uterine leiomyoma and renal cell cancer in this syndrome.

85 Men with cancer (renal-cell cancer in 759 and renal-pelvis cancer in 136)

86 independently increase the long-term risk of renal-cell cancer in men.

87 Renal cell cancer incidence rates increased steadily bet

88 roscopic retroperitoneal lymphadenectomy for renal cell cancer is safe and allows for adequate stagin

89 itors (SMIs) are commonly used in metastatic renal cell cancer (mRCC) patients; patients often develo

90 also known as hereditary leiomyomatosis and renal cell cancer), NRF2 activation is a direct conseque

91 rapy, such as pancreatic, hepatocellular, or renal-cell cancer or melanoma.

92 higher blood pressures and a higher risk of renal-cell cancer (P for trend, <0.001 for diastolic pre

93 n of the Fas(CD95)-R expression on PBLs from renal cell cancer patients compared with normal healthy

94 tched peripheral blood lymphocytes (PBLs) of renal cell cancer patients.

95 observed at or above the MTD in melanoma and renal cell cancer patients.

96 Patients with advanced papillary renal cell cancer (pRCC) have poor survival after system

97 For melanoma and renal cell cancer, prognostic factors were Karnofsky per

98 se-escalation study, which was followed by a renal cell cancer (RCC) dose-expansion cohort.

99 ed LN in patients with advanced melanoma and renal cell cancer (RCC) for therapy.

100 Genome-wide association studies (GWASs) of renal cell cancer (RCC) have identified four susceptibil

101 Renal cell cancer (RCC) incidence has increased in the U

102 Renal cell cancer (RCC) is a heterogeneous disease consi

103 overall survival of patients with metastatic renal cell cancer (RCC) receiving high-dose or one of tw

104 Current drug therapy for metastatic renal cell cancer (RCC) results in temporary disease con

105 Patients with stage IV renal cell cancer (RCC) were vaccinated with irradiated

106 we also performed a comparison analysis with renal cell cancer (RCC)) studies that evaluated sorafeni

107 ast cancer, prostate cancer, bladder cancer, renal cell cancer (RCC), and malignant melanoma data in

108 ile of genes silenced by hypermethylation in renal cell cancer (RCC), we did an expression microarray

109 it is named and the development of sporadic renal cell cancer (RCC).

110 anscription factors and tumor suppressors in renal cell cancer (RCC).

111 ons between reproductive factors and risk of renal cell cancer (RCC).

112 first- or second-line therapy in metastatic renal cell cancer (RCC).

113 pared the transcriptional profile of primary renal cell cancers (RCCs) with that of normal kidney tis

114 s mDC of patients with advanced melanoma and renal cell cancer reduced the activation and Th1 cytokin

115 nce for aldosterone serving a causal role in renal cell cancer regulation via its GPER receptor; thus

116 a (relative risk 3.10, 95% CI 1.26-7.63) and renal cell cancer (relative risk 5.67, 0.66-48.42).

117 o 22+ months) and one of three patients with renal cell cancer (response duration, 14 months).

118 tivariate Cox regression models adjusted for renal cell cancer risk factors, the authors observed tha

119 Renal cell cancer risk increased with increasing body ma

120 size, lifestyle, and medical conditions with renal cell cancer risk was examined among 161,126 Hawaii

121 Hypertension was associated with renal cell cancer (RR-men = 1.42, 95% CI: 1.07, 1.87; RR

122 All 12 renal cell cancers showed a low binding of sst2 with the

123 nger survival among patients with metastatic renal-cell cancer than does interferon therapy alone.

124 on-free survival in patients with metastatic renal cell cancer; the phase II data were confirmed in a

125 ith non-small-cell lung cancer, melanoma, or renal-cell cancer; the adverse-event profile does not ap

126 ccumulation in hereditary leiomyomatosis and renal cell cancer tumors is thought to result from fumar

127 so stratified for the underlying malignancy (renal cell cancer v non-renal cell cancer) and TKI (suni

128 A population-based case-control study of renal cell cancer was conducted in Minnesota between 198

129 PET/CT imaging of 10 subjects with stage IV renal cell cancer was performed after intravenous admini

130 effects of preclinical disease, the risk of renal-cell cancer was still consistently higher in men w

131 w-up (through December 2003), 1,238 cases of renal cell cancer were ascertained.

132 Patients with stage IV melanoma or renal cell cancer were treated every 3 wk with an anti-C

133 f immunotherapeutic approaches in metastatic renal cell cancer, which have produced a consistent demo

134 Most patients with metastatic melanoma and renal cell cancer who achieved PRs or CRs to intravenous

135 were assessed in 39 patients with metastatic renal cell cancer who received a TKI.

136 patients with either metastatic melanoma or renal cell cancer who were treated with high-dose bolus

137 ates were higher in patients with metastatic renal-cell cancer who received sunitinib than in those r

138 e randomly assigned patients with metastatic renal-cell cancer who were acceptable candidates for nep

139 Renal cell cancer with nodal metastases is an independen

140 Whereas the majority of renal cell cancers with histology-associated poor progno